Cubukçu D, Ardiç F, Karabulut N, Topuz O
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
Clin Rheumatol. 2005 Aug;24(4):336-41. doi: 10.1007/s10067-004-1043-z. Epub 2004 Dec 14.
The aim of this study was to investigate the effects of intra-articular hyaluronic acid (HA) on symptoms, functional outcome, and changes in articular cartilage assessed by magnetic resonance imaging (MRI) in patients with knee osteoarthritis. Thirty patients were randomly assigned to treatment with HA (hylan G-F 20, Synvisc) or saline. The treatment group consisted of 20 patients receiving three weekly injections of HA into one or both knees (30 knees). The control group consisted of ten patients receiving three intra-articular injections of 2 ml saline at the same intervals (ten knees). To determine the effectiveness of the HA therapy, all patients were assessed prior to the injections (baseline) and after the 1st, 2nd, 3rd, and 8th weeks. Assessment comprised the following: pain at rest, at night, and on walking using a visual analogue scale (VAS); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, stiffness, and function scores; 15-m walking time; need for analgesics; and evaluation of treatment by the patients. MRI of patellofemoral (PF) articular cartilage was also examined before and after the course of injections at the 8th week. When compared to placebo, a significant statistical difference was found in all clinical parameters. On MRI, although the difference in the PF joint cartilage quality in the HA group before and after the treatment was statistically significant (p < 0.05), this significance was not detected between the groups after the treatment (p > 0.05). After the HA injections, a significant analgesic effect was seen as early as the 3rd week continuing up to the 8th week and functional improvement was seen at the 8th week. In conclusion, intra-articular injections of HA is an effective choice of treatment in patients with knee osteoarthritis.
本研究旨在探讨关节腔内注射透明质酸(HA)对膝关节骨关节炎患者症状、功能结局以及通过磁共振成像(MRI)评估的关节软骨变化的影响。30例患者被随机分为接受HA(海兰G-F 20,施沛特)治疗组或生理盐水治疗组。治疗组由20例患者组成,他们每周接受一次向一侧或双侧膝关节注射HA(共30个膝关节),连续注射三周。对照组由10例患者组成,他们在相同间隔时间内接受三次关节腔内注射2 ml生理盐水(共10个膝关节)。为确定HA治疗的有效性,所有患者在注射前(基线)以及第1、2、3和8周后进行评估。评估内容包括:静息痛、夜间痛和行走痛,采用视觉模拟评分法(VAS);西安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛、僵硬和功能评分;15米步行时间;是否需要使用镇痛药;以及患者对治疗的评价。在第8周注射疗程前后还对髌股(PF)关节软骨进行了MRI检查。与安慰剂相比,所有临床参数均存在显著统计学差异。在MRI上,HA组治疗前后PF关节软骨质量的差异具有统计学意义(p < 0.05),但治疗后两组之间未检测到这种显著性差异(p > 0.05)。HA注射后,早在第3周就出现了显著的镇痛效果,并持续到第8周,且在第8周观察到功能改善。总之,关节腔内注射HA是膝关节骨关节炎患者的一种有效治疗选择。